Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | NNMT | P40261 | 2/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.37 |
| ▸ | TUBB | P07437 | 5/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.37 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.37 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29479358 | 0.84 | ENPP2 (0.41) | ENPP2NNMTERN1ALDH1A1KDM4E | |
| SCHEMBL16115824 | 0.84 | ENPP2 (0.41) | ENPP2NNMTERN1ALDH1A1KDM4E | |
| SCHEMBL29652708 | 0.80 | NNMT (0.51) | NNMTERN1ALDH1A1PDGFRBPDGFRA | |
| SCHEMBL1459819 | 0.80 | NNMT (0.51) | NNMTERN1ALDH1A1PDGFRBPDGFRA | |
| SCHEMBL29953594 | 0.80 | ENPP2 (0.41) | ENPP2ALDH1A1TUBB4ATUBBTUBA3C | |
| SCHEMBL15009942 | 0.78 | ENPP2 (0.39) | ENPP2ERN1ALDH1A1KDM4ETUBB4A | |
| SCHEMBL17629368 | 0.77 | NNMT (0.38) | ENPP2NNMTERN1ALDH1A1KDM4E | |
| SCHEMBL24085430 | 0.76 | NNMT (0.40) | ENPP2NNMTERN1SIRT6GABRP | |
| SCHEMBL20517223 | 0.76 | NNMT (0.47) | ENPP2NNMTERN1ALDH1A1SIRT6 | |
| SCHEMBL5748850 | 0.76 | ENPP2 (0.37) | ENPP2ALDH1A1HPGDTUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-106810557-B | Heterocyclic compounds and their use | 南京圣和药物研发有限公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-2855483-B1 | PYRROLOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| CN-104379574-B | For suppressing the heterocyclic carbamate derivatives of the activity of ABL1, ABL2 and BCR ABL1 | 诺华股份有限公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-104321325-B | Pyrrolopyrrole alkanone compound | 诺华股份有限公司 | 2016-11-16 | — | — | CN | disclosed |
| CN-105801550-A | Novel benzopyran kinase modulators | 理森制药股份公司 | 2016-07-27 | — | — | CN | disclosed |
| US-9365576-B2 | Pyrrolopyrrolidinone compounds | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| CN-104592128-A | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB | 2015-05-06 | — | — | CN | disclosed |
| EP-2855483-A1 | PYRROLOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| CN-104379574-A | Benzamide derivatives for inhibiting the activity of ABL1, ABL 2 and BCR-ABL 1 | NOVARTIS AG | 2015-02-25 | — | — | CN | disclosed |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
| EP-1953165-A1 | AZA-SUBSTITUTED SPIRO DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-08-06 | — | — | EP | disclosed |
| CN-101229164-A | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2008-07-30 | — | — | CN | disclosed |
| CN-100384423-C | Compositions and antiviral activity of substituted azaindoloxoacetylpiperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2008-04-30 | — | — | CN | disclosed |
| CN-100379421-C | Compositions and antiviral activity of substituted azaindoloxoacetylpiperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2008-04-09 | — | — | CN | disclosed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | disclosed |
| CN-1688311-A | Compositions and antiviral activity of substituted azaindoloxoacetylpiperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2005-10-26 | — | — | CN | disclosed |
| CN-1612763-A | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL MYERS SQUIBB CO (US) | 2005-05-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | ENPP2 509/4885NNMT 1191/4885ERN1 1660/4885 |
| US-20090258871-A1 | Aza-Substituted Spiro Derivatives | AZI2, NR3C2, DNMT3A | ENPP2 3529/4885NNMT 521/4885ERN1 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.